CLINICAL TRIALS PROFILE FOR MESALAMINE
✉ Email this page to a colleague
All Clinical Trials for MESALAMINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00063414 ↗ | ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis | Completed | Ionis Pharmaceuticals, Inc. | Phase 2 | 1969-12-31 | This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of alicaforsen delivered by enema over a six-week period as compared to an active control, mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6. |
| NCT00098111 ↗ | Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease | Terminated | Massachusetts General Hospital | Phase 3 | 2005-04-01 | The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects. |
| NCT00109473 ↗ | Trial of Growth Hormone Therapy in Pediatric Crohn's Disease | Completed | Genentech, Inc. | Phase 2 | 2005-04-01 | The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug. |
| NCT00109473 ↗ | Trial of Growth Hormone Therapy in Pediatric Crohn's Disease | Completed | Children's Hospital Medical Center, Cincinnati | Phase 2 | 2005-04-01 | The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug. |
| NCT00151892 ↗ | Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis | Completed | Shire | Phase 3 | 2005-04-08 | Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and abdominal pain followed by periods of time without disease symptoms. 5-ASA drugs are a standard treatment for ulcerative colitis. Mesalazine is an experimental drug designed to gradually release 5-ASA into the areas of large bowel associated with ulcerative colitis. This study will test the safety and efficacy of mesalazine in keeping ulcerative colitis in remission. |
| NCT00194818 ↗ | Asacol Dosing Study for Active Ulcerative Colitis | Completed | Procter and Gamble | Phase 4 | 2003-06-01 | We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects. |
| NCT00194818 ↗ | Asacol Dosing Study for Active Ulcerative Colitis | Completed | University of Washington | Phase 4 | 2003-06-01 | We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MESALAMINE
Condition Name
Clinical Trial Locations for MESALAMINE
Trials by Country
Clinical Trial Progress for MESALAMINE
Clinical Trial Phase
Clinical Trial Sponsors for MESALAMINE
Sponsor Name
